International Journal of Breast Cancer / 2018 / Article / Tab 3

Research Article

CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

Table 3

CDK9 expression and breast cancer subtype/receptor status. This tables shows no significant association of CDK9 expression with breast cancer subtype and receptor status.

CovariateStatisticsLevelNegative N=31Positive N=36P-value

ER statusN (Col %)Negative14 (46.67)9 (25)0.066
N (Col %)Positive16 (53.33)27 (75)

PR statusN (Col %)Negative17 (56.67)12 (33.33)0.057
N (Col %)Positive13 (43.33)24 (66.67)

Her2Neu statusN (Col %)Negative23 (76.67)30 (83.33)0.498
N (Col %)Positive7 (23.33)6 (16.67)

SubtypeN (Col %)Triple negative10 (34.48)7 (19.44)0.088
N (Col %)ER+/PR+/Her2Neu-9 (31.03)21 (58.33)
N (Col %)Other10 (34.48)8 (22.22)

Age at diagnosis (years)N (Col %)<5011 (35.48)14 (38.89)0.774
N (Col %)50+20 (64.52)22 (61.11)

StageN (Col %)216 (53.33)20 (57.14)0.758
N (Col %)314 (46.67)15 (42.86)

The p-value is calculated by chi-square test or Fisher’s exact, where appropriate.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.